Sanofi stock rises on vaccine approval and valuation support

Published on 09/04/2026 at 18:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi stock gains support from a regulatory vaccine update and a market value of EUR 91.49 billion on September 3, 2026. The latest reported quarter showed EPS of USD 36.26 and a negative surprise versus consensus.

Schwarzweiß-Reportagefoto einer Newsroom-Redaktion mit Blick auf Paris — Vivendi SE (FR0000127771) zählt zu Frankreichs Medienkonzernen; die Schwarzweiß-Reportage zeigt eine Pariser Redaktion, Illustration mit AI erstellt.

Sanofi stock (FR0000127771) has fresh support after partners Sanofi and Takeda received regulatory approval for the XFG-adapted Nuvaxovid COVID-19 vaccine for the 2026-2027 season in the United States, Europe and Japan, according to an RTTNews report dated September 4, 2026. The same report says Sanofi will lead commercialization in key markets, while Takeda keeps exclusive rights in Japan.

Market value and price gap

The market snapshot on September 3, 2026 put Sanofi at EUR 76.27, with a market capitalization of EUR 91.49 billion and a one-day move of 1.21 percent in the linked analysis from Danelfin. That price sits 26 percent below the EUR 107 fair value cited in the same note.

For investors, the valuation gap is the number to watch, because the share price and the implied upside are now easy to compare in one line. The move is modest, but the market cap still gives Sanofi heavyweight status in European pharma.

Latest reported quarter

Sanofi's most recent reported quarter was Q2 2026, with revenue of USD 1.547 billion and non-GAAP EPS of USD 0.62, according to the earnings call transcript on September 4, 2026. Revenue beat the company guide of USD 1.415 billion to USD 1.420 billion, while EPS topped the market estimate of USD 0.45.

The same transcript says non-GAAP operating margin reached 15.3 percent, above the 12.5 percent guide, and that adjusted EPS came in about 38 percent above the estimate. That combination matters more than the headline beat alone.

Go deeper

Sanofi in the latest quarter

The Q2 2026 call and the vaccine approval frame the short-term setup for Sanofi stock.

Vaccine sales driver

Nuvaxovid remains the clearest product angle in this move, because the newly approved 2026-2027 season gives Sanofi a commercial link to a still-visible respiratory vaccine franchise. The approval also adds a dated catalyst to a stock that is already trading on a large-cap valuation base.

Trading level

Sanofi stock was last quoted at EUR 76.27 on September 3, 2026, with a market capitalization of EUR 91.49 billion in the same market snapshot. The share therefore trades well below the EUR 107 fair value named in the same analysis.